Operator Good day, and welcome to the Vertex Pharmaceuticals fourth quarter 2024 earnings call. All participants will be in a ...

Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) reported Q4 CY2024 results exceeding the market’s revenue expectations, ...

Vertex Pharmaceuticals forecast annual revenue largely above Wall Street estimates on Monday, banking on robust sales of its ...

Vertex reports mixed fourth-quarter 2024 results as earnings miss estimates while revenues beat the same. Trikafta/Kaftrio ...

Q4 2024 Earnings Call Transcript February 10, 2025 Vertex Pharmaceuticals Incorporated misses on earnings expectations. Reported EPS is $3.98 EPS, expectations were $4.02. Operator: Good day, and ...

Biotechnology company Vertex Pharmaceuticals (VRTX) reported mixed results for the fourth quarter of 2024. While revenue surpassed analyst ...

The company posted quarterly adjusted earnings of $3.48 per share which missed the analyst consensus estimate of $4.03 per ...

Reports Q4 revenue $2.91B, consensus $2.78B. “2024 marked a year of tremendous growth for Vertex and we anticipate 2025 will be another ...

Vertex Pharmaceuticals Inc. will soon lose a member of its leadership team that helped the company achieve major revenue ...

Vertex Pharmaceuticals (VRTX) reports Q4 earnings today. Investors are eager for updates on new drug launches and growth ...

Vertex Pharmaceuticals dominates the market for ... up nearly 39% from the IPO price. In cystic fibrosis (CF), genetic mutations lead to faulty versions of CFTR, a protein key to moving ions ...

Activist hedge fund Elliott Investment Management has grown its stake in Phillips 66 ( PSX 4.01%) to $2.5 billion. This puts ...